Ray McDermott, discusses preventing recurrence in patients with very high-risk prostate cancer.
Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI
Advertisement
Articles by Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI
Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the design of the DASL-HiCAP trial in high-risk prostate cancer.
Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the next steps of the phase 3 DASL-HiCAP trial in high-risk prostate cancer.
Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the rationale for the addition of darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk prostate cancer.
Advertisement
Latest Updated Articles
Dr. McDermott on Preventing Recurrence of High-Risk Prostate CancerOctober 21st 2020
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
3
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
4
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
5